STRO Stock Forecast & Price Target

Sutro Biopharma is a clinical-stage drug discovery and development company with a strong and diverse pipeline targeting various cancers and autoimmune disorders. With five active programs expected by 2027 and favorable safety profiles shown by their lead candidate STRO-004, the company has potential value in the mid-to-long term. However, there are inherent risks with drug development, partnerships, competition, and financials that could impact their success. With a focus on their innovative platform and potential for multiple indications, the company could see a valuation increase up to $50 per share, but risks must be carefully considered.

Sutro Biopharma is showing encouraging early data from its STRO-004 Phase 1 study, with confirmed and ongoing unconfirmed PRs observed in multiple solid tumor types at doses of 3-4 mg/kg. Tolerability appears differentiated relative to Tivdak, with predominantly low-grade AEs and no neuropathy or ILD/pneumonitis signals reported. The company ended 1Q26 with a strengthened balance sheet and expects to fund operations into at least 2Q28, but we believe the weak initial dataset and lack of a disclosed ORR creates an attractive entry point ahead of upcoming updates.